In a phase 1 study, DLTs occurred in 1/3 patients with advanced solid tumors treated with the ERK inhibitor GDC-0994 200 mg plus the MEK inhibitor cobimetinib 40 mg once daily (grade 3 diarrhea) and 2/6 patients treated with GDC-0994 200 mg plus cobimetinib 80 mg once daily (grade 3 myocardial infarction, grade 3 rash and acneiform dermatitis) [21]. This evidence concerns the gene MAP2K7 and myocardial infarction.